Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning, morning. Today, we have a trio of interesting studies on cholesterol reduction from the American Heart Association’s meeting in New Orleans. Also, Pfizer wins the Metsera deal with $10 billion, and we look at Trump’s GLP-1 deal more closely.

The need-to-know this morning

Cogent Biosciences said its experimental drug, called bezuclastinib, lowered the risk of tumor progression or death by 50% compared to a standard treatment for advanced gastrointestinal stromal tumors — meeting the primary goal of a Phase 3 study.

How impactful could Trump’s GLP-1 deal be?

President Trump’s GLP-1 deal with Novo Nordisk and Eli Lilly last week marked a major policy

See Full Page